Groundbreaking protein atlas reveals cellular insights for disease research

Real-world outcomes of patients with relapsed/refractory multiple myeloma treated with the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel (cilta-cel, Carvykti) showed “favorable” efficacy results,

Back in Jan­u­ary, Take­da won ap­proval for a new in­di­ca­tion for its pri­ma­ry im­mun­od­e­fi­cien­cy drug HyQvia, this time as a treat­ment for a rare au­toim­mune